U.S. Retinal Therapeutics Market

U.S. Retinal Therapeutics Market

 

RELEASE DATE
07-Jun-2011
REGION
North America
Research Code: N85D-01-00-00-00
SKU: HC02172-NA-MR_07791
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC02172-NA-MR_07791

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the "Product Pipeline" section of this research service.

Table of Contents

U.S. Retinal Therapeutics Market

  • Introduction

Research Scope and Methodology

  • Scope and Segmentation
  • Research Methodology

Market Overview

  • Introduction
  • Disease Overviews

Clinical Need and Burden of Disease

  • Age-related Macular Degeneration
  • Diabetic Retinopathy and Diabetic Macular Edema
  • Retinal Vein Occlusion

Market Trends

  • Market Engineering Measurements
  • Industry Challenges and Strategies
  • Market Drivers

Market Outlook and Revenue Forecasts

Competitive Overview

This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the 'Product Pipeline' section of this research service.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number N85D-01-00-00-00
Is Prebook No